Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

54.76 +3.54 (+6.91%)

Streaming Delayed Price Updated: 3:51 PM EDT, Apr 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

35 36 Next >

3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later ↗

January 25, 2023

Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.

Via InvestorPlace

3 Gene Editing Stocks With the Best Long-Term Potential ↗

January 25, 2023

These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space

Via InvestorPlace

Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics? ↗

January 22, 2023

Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.

Via The Motley Fool

3 Smart Stocks to Buy if a Recession Is on the Way ↗

January 21, 2023

Their products will enjoy strong demand regardless of what happens with the economy.

Via The Motley Fool

CRISPR Therapeutics Stock: Bull vs. Bear ↗

January 19, 2023

Should investors buy this risky biotech stock as the company moves toward bringing its first major treatment to market?

Via The Motley Fool

7 Biotech Stocks That Will Make You Rich in 10 Years ↗

January 18, 2023

Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.

Via InvestorPlace

5 Reasons to Buy Vertex Pharmaceuticals Now ↗

January 18, 2023

Vertex shares are extending last year's gains, and that trend probably isn't over.

Via The Motley Fool

Is It Too Late to Buy Vertex Pharmaceuticals Stock? ↗

January 14, 2023

Vertex is heading for a new phase of growth.

Via The Motley Fool

3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years ↗

January 18, 2023

CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in 10 years.

Via InvestorPlace

2 Stocks Down More Than 25% to Buy Right Now ↗

January 16, 2023

These companies are set for a new era of growth.

Via The Motley Fool

5 Potentially Explosive Stocks to Buy in 2023 ↗

January 13, 2023

These stocks all dropped in the double digits last year. But their future prospects are brilliant.

Via The Motley Fool

More Likely to 5X First: CRISPR Therapeutics vs. InMode ↗

January 12, 2023

These two companies are in very different situations but could generate significant returns for investors.

Via The Motley Fool

2 Growth Stocks You May Regret not Buying Right Now ↗

January 11, 2023

At their beaten-down valuations, these stocks have the potential to deliver some impressive returns.

Via The Motley Fool

Can Cathie Wood Bounce Back in 2023? ↗

January 11, 2023

Wood sticks by her strategy, no matter what the general market does.

Via The Motley Fool

Expert Ratings for CRISPR Therapeutics ↗

January 05, 2023

Via Benzinga

2 Supercharged Stocks to Buy Right Now That Could Soar in 2023 ↗

January 11, 2023

These stocks have been solid performers despite the macroeconomic uncertainties in 2022.

Via The Motley Fool

2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years ↗

January 07, 2023

Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow.

Via The Motley Fool

2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

January 06, 2023

These biotechnology stocks are pushing ahead with promising innovations.

Via The Motley Fool

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗

January 06, 2023

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

Via Investor's Business Daily

Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away' ↗

January 04, 2023

Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Rich Over Time ↗

January 04, 2023

Wood is bargain hunting now. And these buys may pay off big in the long run.

Via The Motley Fool

3 Growth Stocks That Could Skyrocket 50% or More In 2023, According to Wall Street ↗

December 31, 2022

These stocks fell significantly in 2022. But analysts expect that huge rebounds could be on the way in the new year.

Via The Motley Fool

1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now) ↗

December 30, 2022

Both stocks have fallen brutally this year, but only one has a chance to recover soon.

Via The Motley Fool

2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond ↗

December 29, 2022

These two biotechs are flying high right now.

Via The Motley Fool

5 Unstoppable Trends to Invest $5,000 in for 2023 ↗

December 29, 2022

These trends won't fade away, and some of the companies that are positioned to ride them should be big winners.

Via The Motley Fool

Could CRISPR Therapeutics Help You Become a Millionaire? ↗

December 27, 2022

The gene-editing stock still has plenty of promise.

Via The Motley Fool

Is Vertex Pharmaceuticals a Buy? ↗

December 27, 2022

There's more growth ahead for this biotech giant.

Via The Motley Fool

After Doubling in the Past 6 Months, Is This Stock a Buy? ↗

December 24, 2022

This company has had a solid year, but there is still plenty of work ahead.

Via The Motley Fool

Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023? ↗

December 22, 2022

Crispr and Vertex are working toward the first submissions for a CRISPR-based product.

Via Investor's Business Daily

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.